REGULATORY

• PMDA Mulls Fee Raise for Drug, Device Reviews
  November 4, 2016

• Medical Corporation in Tokyo Ordered to Temporarily Suspend Regenerative Medicine Service: MHLW
  November 4, 2016

• MHLW Struggling to Set Date for Chuikyo Subcommittee Discussions on Opdivo
  November 2, 2016

• MHLW Panel Backs Ono’s Hyperparathyroidism Drug Etelcalcetide
  November 1, 2016

• PMDA Had 71 Individual Interviews in Regulatory Strategy Consultation Services in April-September 2016
  November 1, 2016

• Inisync, 4 Other DPP-4 Inhibitors Under PMDA Risk Review
  October 31, 2016

• Postponed PAFSC 2nd Committee Meeting Set for November 11
  October 31, 2016

• MID-NET Working Group Discusses Access Fee Calculations
  October 28, 2016

• Long-Listed Drug Use by Welfare Recipients Should Require Copay: MOF
  October 28, 2016

• Panel Negative about Singling Out OTC-Switched Rx for Health Coverage Talks, Calls for Broader Discussions
  October 27, 2016

• Shiozaki Does Not Rule Out Price Cut of Over 25% for Opdivo
  October 27, 2016

• MHLW Alerts on Risk of Fulminant Type 1 Diabetes for Keytruda
  October 25, 2016

• Pharma Groups Tender Requests to LDP on FY2017 Budget, Tax Reform
  October 24, 2016

• Govt Panel Members Call for Drastic Drug Pricing Reform, Annual Revision
  October 24, 2016

• Keytruda’s November Listing Skip Likely amid Opdivo Re-Pricing Fuss
  October 24, 2016

• New Govt Panel Holds 1st Meeting for Healthcare, Long-Term Care
  October 21, 2016

• MHLW Panel to Discuss Health Coverage of Ethical Drugs with OTC Versions on Oct. 26
  October 21, 2016

• Oct. 27 MHLW Panel Meeting Postponed Due to Lack of Quorum
  October 21, 2016

• Basic Policy on JP 18th Edition Calls for Expansion of Sections Related to Biopharmaceuticals: MHLW
  October 21, 2016

• Heads of Medicines Regulatory Agencies to Hold Summit in Kyoto Next October
  October 20, 2016

ページ

• « 先頭
• ‹ Prev
• …
• 268
• 269
• 270
• 271
• 272
• 273
• 274
• 275
• 276
• …
• Next ›
• 最終 »